(AVD) American Vanguard Corporation BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(AVD) American Vanguard Corporation Complete Analysis Pack
Unlock Strategic Clarity
This American Vanguard Corporation BCG Matrix helps you quickly see how the company’s products or business units may fit into the four classic quadrants: Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Aztec 4.67G corn franchise
Aztec 4.67G is one of American Vanguard Corporation’s best-known row-crop brands, and it fits a Star well because it serves corn insect and nematode control in a huge market. U.S. farmers planted about 90 million corn acres in 2025, so demand stays broad even in a niche segment. Strong brand reach plus recurring pest pressure keeps this franchise strategically important.
Capture LFR seed treatment
Capture LFR fits a growth-star profile: seed-applied insect protection keeps gaining use in row crops, and the category scales with planted acres and pest pressure. It still needs channel push and seasonal promotion, but that support can convert adoption into repeat demand.
Impact herbicide
Impact fits a Star because herbicide resistance keeps it relevant in crop programs. Global herbicide resistance has been confirmed in 260+ weed species across 100+ crops, with resistance documented to 15 sites of action, so growers still pay for rotation tools. If American Vanguard holds share, Impact can keep driving growth-led revenue.
Nimitz 2EC nematicide
Nimitz 2EC, built on fluensulfone at 2.0 lb/gal, fits the Star bucket because nematode pressure can trim 10% to 30% of yield in high-value crops, so growers pay for protection, not discretion. Its specialty-label profile supports expansion across row crops and fruit/veg as an acre-by-acre yield defense.
- Yield protection drives demand.
- Best fit in high-value acres.
- Expansion label, not a niche fix.
Latin America crop protection
AMVAC’s Latin America crop protection business fits a Star if it keeps scaling faster than the mature U.S. market. In 2025, American Vanguard reported net sales of about $557 million, and management said international growth, including Latin America, remained a key offset to softer U.S. demand. That matters because crop-protection use in Brazil and nearby markets is still tied to acreage growth, pest pressure, and distributor build-out.
- Growth market, not mature channel
- Share rises with local distribution
- Can turn into a Star quickly
American Vanguard’s Star Brands Tap Massive U.S. Crop Demand
American Vanguard Corporation’s Stars are the brands with the clearest growth tailwinds, led by Aztec 4.67G, Capture LFR, Impact, and Nimitz 2EC. In 2025, U.S. corn acreage was about 90 million acres, and American Vanguard reported about $557 million in net sales, so these products sit in large, active demand pools. Their value comes from recurring pest pressure, resistance management, and yield protection.
| Star | Why it fits | Key fact |
|---|---|---|
| Aztec 4.67G | Corn pest control | ~90M U.S. corn acres |
| Nimitz 2EC | Nematode defense | 10% to 30% yield risk |
What is included in the product
Detailed Word Document
BCG snapshot of American Vanguard’s portfolio, highlighting Stars, Cash Cows, Question Marks, and Dogs with clear invest/hold/divest cues.
Editable Excel File
BCG Matrix for American Vanguard Corporation to quickly pinpoint and ease portfolio allocation pain points.
Reference Sources
Strengthens confidence in American Vanguard Corporation analysis by tying key claims to credible, traceable reference sources.
Cash Cows
Thimet 20G
Thimet 20G is a legacy specialty insecticide and nematicide with mature, stable demand, so American Vanguard Corporation can support sales with limited promotion. That fits cash-cow economics: low growth, steady harvest, and less capital needed to defend the brand. In 2025, this kind of mature product logic is exactly what protects cash flow in a slow market.
Counter 20G
Counter 20G fits Cash Cows because it is a mature granular crop-protection brand with steady, niche demand and low growth needs. American Vanguard Corporation reported net sales of $529.6 million in FY2024, and brands like Counter help support cash flow through repeat use and strong name recognition. It is not a growth driver, but it can keep generating cash with limited new investment.
Mocap 15G
Mocap 15G has long sat in American Vanguard Corporation’s portfolio, and its mature, narrow-use market supports steady repeat demand. In a low-growth crop protection niche, that profile usually means dependable cash flow more than expansion. For the BCG Matrix, Mocap fits the Cash Cow role because volume is stable, competition is entrenched, and capital needs stay limited.
Folex 6EC
Folex 6EC fits the Cash Cows box because it is a recognized cotton defoliant brand in a crop input market that is seasonal, mature, and easy to forecast. That supports repeat demand and steadier cash generation, but it does not point to fast growth.
Seasonal cotton use
Known, stable demand pattern
Steady income, low growth
For American Vanguard Corporation, Folex 6EC looks more like a dependable profit contributor than a capital-heavy growth driver.
Turf and ornamental distribution
AMVAC’s turf and ornamental business runs through distributors and agents, so it depends on mature, relationship-led channels with steady reorders. That fits cash-cow traits: low growth, repeat demand, and less need for heavy selling spend. In FY2025, this channel likely stayed a stable base for AMVAC’s crop-protection sales mix.
- Distributor-led, repeat-order channel
- Mature turf and ornamental demand
- Steady cash generation profile
American Vanguard’s Cash Cows Keep Cash Flow Steady
Cash cows at American Vanguard Corporation are mature, repeat-use brands that keep cash coming in with little extra spend. Thimet 20G, Counter 20G, Mocap 15G, and Folex 6EC fit that role because demand is stable, niche, and seasonal. FY2024 net sales were $529.6 million, so these brands help protect cash flow in a slow-growth mix.
| Cash Cow | Why it fits |
|---|---|
| Thimet 20G | Legacy demand, low promo need |
| Counter 20G | Mature niche brand, repeat use |
| Mocap 15G | Stable volume, limited capital |
Full Version Awaits
American Vanguard Corporation Reference Sources
The American Vanguard Corporation BCG Matrix preview you see is the exact same document you’ll receive after purchase. There are no demo pages or hidden changes—just the full, ready-to-use report. Once purchased, it’s instantly available for your strategic review, editing, or presentation.
Dogs
Dacthal W-75
Dacthal W-75 is a clear Dog for American Vanguard Corporation: U.S. regulators moved to cancel its registrations in 2024 after EPA cited acute risks to unborn babies and farmworkers. With label risk now dominating the story, the product has little visible growth runway and a weak long-term economic case. In BCG terms, it is a legacy asset with high downside and limited strategic value.
Legacy organophosphates
In American Vanguard Corporation’s FY2025 mix, legacy organophosphates like phorate, terbufos, and ethoprop remain sellable but are mature, tightly constrained, and not growth drivers. Their shrinking strategic role and rising regulatory pressure make them fit Dog status more than Cash Cow status.
Small consumer pest lines
AMVAC is mainly an agricultural specialty-chemicals Company, so its small consumer pest lines sit outside the core crop-protection engine. In BCG terms, these lines have low scale and weak growth, so they act like Dogs. That usually means limited cash return and little strategic pull versus AMVAC's larger crop portfolio.
Low-volume technical sales
Low-volume technical sales in American Vanguard Corporation’s Dogs category can lift shipments, but commodity pricing keeps margins thin, so capital tied up in these lines tends to earn weak returns. With no clear demand edge, they rarely build share or momentum, which fits a low-growth, low-share profile in the BCG matrix.
- Volume helps, margin often does not.
- No differentiation, no lasting share gain.
- Capital is better used elsewhere.
Older turf formulations
Older turf formulations fit the Dogs box because turf and ornamental markets are mature, price-led, and hard to defend without a clear performance edge. When products lose differentiation, they face commoditization, so margins tend to shrink and capital returns stay weak. In American Vanguard Corporation's latest filings, that kind of portfolio drag is exactly the sort of business unit that can become a low-return hold.
- Weak differentiation
- Price pressure
- Low margin potential
- Dog-like cash use
FY2025 Dogs: Legacy Products Under Regulatory Pressure
Dogs in American Vanguard Corporation’s FY2025 mix are legacy, low-share products with weak growth and heavy regulatory drag. Dacthal W-75 is the clearest case: EPA moved to cancel its U.S. registrations in 2024 after acute risk findings for unborn babies and farmworkers. Older organophosphates and small consumer/turf lines also fit Dog status.
| Dog segment | FY2025 signal |
|---|---|
| Dacthal W-75 | EPA cancellation move |
| Legacy organophosphates | Mature, constrained |
| Consumer/turf lines | Low scale, low growth |
Question Marks
Azera biological insecticide
Azera biological insecticide fits the Question Mark box because biological crop protection is growing fast, but biologicals still usually launch with small share versus legacy chemistries. AMVAC gets a foothold in a segment that can grow at double-digit rates, yet Azera has not reached the scale of the company’s core synthetic brands. That means high upside, but it needs spend on sales, trials, and grower adoption to move toward Star status.
Requiem bioinsecticide
Requiem bioinsecticide fits a Question Mark: bioinsecticides are growing fast as growers seek residue-free and resistance-management tools, but the field is crowded and split across many niche rivals. The global biological crop protection market was about $6.5 billion in 2025, still a small share of the roughly $70 billion crop protection market, so share gains need spend. Requiem likely needs more marketing and field support before it can move toward a Star.
Venerate bioinsecticide
Venerate bioinsecticide fits the Question Marks box because it sits in the fast-growing biologicals market, but American Vanguard Corporation still has limited scale there. The upside is real, since biological crop inputs keep taking share from chemistries, yet Venerate is not a dominant brand today. That makes it a buy-and-build asset: invest to lift distribution, margin, and share before it can move toward a Star.
Plant nutrition products
Plant nutrition products fit American Vanguard Corporation’s Question Marks: soil health demand is rising, but these lines still lack the scale and brand lock-in of core crop-protection franchises. They can win adoption in specialty ag, yet they usually need heavy selling and field trials before margins improve.
- Growth theme, weak share.
- Needs investment to scale.
- Prune if adoption stays slow.
That makes them invest-or-prune candidates, not cash cows. The key test is whether 2026 sales can beat the cost of channel support, product education, and farmer switching friction.
New biological seed treatments
New biological seed treatments fit American Vanguard Corporation’s question-mark box: the category is growing fast, but dealer pull, farmer proof, and repeat orders still take time. Seed-treatment biology can win share in a market that is expanding at a high-single to low-double-digit pace, but only if field results are consistent.
That makes the segment promising, but not yet a cash cow; until adoption broadens, it needs investment in trials, channel support, and data-backed performance claims.
- High growth, low share
- Proof drives adoption
- Dealer support matters
- Scale decides future status
American Vanguard’s Growth Bets: High Upside, Still Low Share
American Vanguard Corporation’s Question Marks are the biologicals and plant nutrition lines: they sit in fast-growing niches, but share is still small and needs more spend, trials, and channel support to scale. With the biological crop protection market near "$6.5 billion" in 2025 versus about "$70 billion" for total crop protection, the upside is real, but only if adoption keeps rising.
| Segment | 2025 signal | BCG view |
|---|---|---|
| Biologicals | Fast growth, low share | Question Mark |
| Plant nutrition | Needs proof and scale | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.